# Chengdu Zenitar Biomedical Technology trials: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials with Chengdu Zenitar Biomedical Technology Co., Ltd as lead sponsor, 13 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Chengdu Zenitar Biomedical Technology Co., Ltd: 24 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 13
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946783 | A Phase I Clinical Study of Oral ZL-65 Tablets in Healthy and Obese Participants With Cardiovascular Risk | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Not yet recruiting | Obesity With Cardiovascular Risk Study | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946783) |
| September 9, 2026 | NCT07809217 | Mass Balance Study of \[¹⁴C\]Purinostat Mesylate for Injection in Healthy Participants | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Recruiting | MB | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809217) |
| August 17, 2026 | NCT07768111 | Clinical Study on Drug Interactions of Flonoltinib Maleate Tablets | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Not yet recruiting | Drug Interaction Research | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768111) |
| August 11, 2026 | NCT07757152 | Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Recruiting | Healthy Participants Study | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757152) |
| August 6, 2026 | NCT07750574 | Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Not yet recruiting | Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750574) |
| May 28, 2026 | NCT07612306 | Mass Balance Study of \[14C\] Flonoltinib Maleate | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Completed | MB | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612306) |
| March 2, 2026 | NCT07443306 | A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate... | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Recruiting | MF | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443306) |
| January 14, 2026 | NCT07339748 | A Clinical Study of ZL-85FA Tablets | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339748) |
| January 5, 2026 | NCT07317700 | A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 3 | Recruiting | MF | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07317700) |
| November 18, 2025 | NCT07232290 | Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Recruiting | Polycythemia Vera (PV) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07232290) |
| September 26, 2025 | NCT07193589 | A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Recruiting | Atopic Dermatitis | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193589) |
| September 26, 2025 | NCT07193576 | A Pharmacokinetic Study of the Food Effect on Flonoltinib Maleate Tablets | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Completed | Heathly Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193576) |
| June 8, 2025 | NCT07011056 | A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 3 | Recruiting | Recurrent and Refractory Diffuse Large B-cell Lymphoma | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011056) |
| July 3, 2024 | NCT06485219 | A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Active not recruiting | Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06485219) |
| July 3, 2024 | NCT06484829 | Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06484829) |
| June 13, 2024 | NCT06457425 | A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Active not recruiting | MF,PMF,PPV-MF,PET-MF | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06457425) |
| May 29, 2024 | NCT06432738 | ZL-82 Double-blind Clinical Trial | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Completed | Healthy Person | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06432738) |
| May 28, 2024 | NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1/2 | Recruiting | Advanced Solid Tumor | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06431243) |
| April 29, 2024 | NCT06387966 | A Phase I Clinical Study of Flonoltinib Maleate Tablets in Healthy Subjects | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Completed | Heathly Subjects | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06387966) |
| September 26, 2023 | NCT06055023 | Phase I Clinical Study of ZL-82 Tablets | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Completed | Rheumatoid Arthritis (RA), Inflammatory Bowel Disease - IBD1 | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06055023) |
| February 6, 2023 | NCT05713279 | Study of Flonoltinib Maleate Tablets in the Treatment of Severe Novel Coronavirus (COVID-19) Infection | Chengdu Zenitar Biomedical Technology Co., Ltd | Not applicable | Terminated | COVID-19 | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05713279) |
| October 3, 2022 | NCT05563844 | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Active not recruiting | Diffuse Large B Cell Lymphoma，DLBCL | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05563844) |
| September 2, 2022 | NCT05526313 | Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1 | Completed | Diffuse Large B Cell Lymphoma，DLBCL | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05526313) |
| December 10, 2021 | NCT05153343 | Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 1/2 | Completed | Myeloproliferative Neoplasm (MPN), Myelofibrosis，MF | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05153343) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 4 |
| Phase 2 | 7 |
| Phase 3 | 2 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 9 |
| Completed | 7 |
| Not yet recruiting | 4 |
| Active not recruiting | 3 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Recurrence | 3 |
| Dendritic Cell Sarcoma, Interdigitating | 2 |
| Lymphoma, T-Cell, Peripheral | 1 |
| Lymphoma, T-Cell, Cutaneous | 1 |
| Multiple Myeloma | 1 |
| Primary Myelofibrosis | 1 |
| Anemia | 1 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Dermatitis, Atopic | 1 |
| Polycythemia Vera | 1 |
| Arthritis, Rheumatoid | 1 |
| Crohn Disease | 1 |
| COVID-19 | 1 |
| Myeloproliferative Disorders | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Propane suppliers in the United States](https://specstream.ai/data/businesses/propane-suppliers/united-states)
- [Builders in the United States](https://specstream.ai/data/businesses/builders/united-states)
- [Leather products manufacturers in the United States](https://specstream.ai/data/businesses/leather-products-manufacturers/united-states)
- [Wallpaper installers in the United States](https://specstream.ai/data/businesses/wallpaper-installers/united-states)
- [Farm equipment suppliers in the United States](https://specstream.ai/data/businesses/farm-equipment-suppliers/united-states)
- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
